Acute Graft Versus Host Disease in Intestine
0
Pipeline Programs
1
Companies
2
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
1 companies ranked by most advanced pipeline stage
MaaT PharmaFrance - Lyon
2 programsMaaT013N/A1 trial
MaaT013PHASE_31 trial
Active Trials
NCT04768907Available
Trial Timeline
Clinical trial activity over time
2022
2023
2024
2025
2026
MaaT PharmaMaaT013
Clinical Trials (2)
Total enrollment: 66 patients across 2 trials
MaaT013 As Salvage Therapy in Ruxolitinib Refractory GI-aGVHD Patients
Start: Mar 2022Est. completion: Nov 202566 patients
Phase 3Active Not Recruiting
Early Access Program With MaaT013 in Steroid-refractory Acute Gastrointestinal Graft Versus Host Disease
N/AAvailable
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.